INTERACTION OF NANOSTRUCTURED LIPID CARRIERS WITH HUMAN MEIBUM
Objective: This study aimed to determine the possibility of nanostructured lipid carriers (NLCs) as a bionic tear film by determining the surface activities of the developed NLCs and their interaction with human meibomian lipid films.Â
Methods: NLCs with different types of solid lipids and surfactants were prepared by a high pressure homogenizer. The particle size was determined by dynamic light scattering. The surface activities of the NLCs and NLCs mixed with meibomian lipids were measured using a Langmuir trough and the resulting surface pressure area (Î -A) profiles were compared. These lipid films were further analyzed using fluorescence microscopy and scanning electron microscopy (SEM).Â Â
Results: The particle size of prepared NLCs varied from 38 â€“ 280 nm based on types of solid lipid and surfactant. All NLCs were highly surface active as indicated by their maximum surface pressure (Î max). The Î -A profiles of meibum seeded with NLCs showed higher surface pressure than meibum alone and the shape of profiles were dominated by the meibomian lipids. These findings were in agreement with fluorescence and SEM micrographs, which revealed that the NLCs could adsorb and integrate to the meibomian lipid films as well as diffuse from the subphase to the lipid films.
Conclusion: NLCs are surface active and can integrate with meibomian lipid films formed stable films. The type of interaction can be tailored by altering the solid lipids used in the formulation of the NLCs which could provide the means to develop efficient formulations for targeting dry eye disease related to a non-functional tear film lipid layer.
2. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf 2004; 2: 149-65.
3. Millar TJ, Schuett BS. The real reason for having a meibomian lipid layer covering the outer surface of the tear film â€“ A review. Exp Eye Res 2015; 137: 125-38.
4. Butovich IA, Wojtowicz JC, Molai M. Human tear film and meibum. Very long chain wax esters and (O-acyl)-omega-hydroxy fatty acids of meibum. J lipid Res 2009; 50: 2471-85.
5. Lam SM, Tong L, Yong SS, Li B, Chaurasia SS, Shui G, Wenk MR. Meibum Lipid Composition in Asians with Dry Eye Disease. PLoS ONE 2011; 6:1-13
6. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012; 130: 90-100.
7. Barabino S, Chen Y, Chauhan S, Dana R. Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res 2012; 31: 271-85.
8. Kasetsuwan N, Reinprayoon U. A sodium hyaluronate ophthalmic solution for reducing dry eye and enhancing corneal wound healing after photorefractive keratectomy (PRK). Asian JPharmClin Res 2015; 8: 226-31.
9. AraÃºjo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009; 5: 394-401.
10. Hao J, Wang F, Wang X, Zhang D, Bi Y, Gao Y, Zhao X, Zhang Q. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eur J Pharm Sci 2012; 47: 497-505.
11. Tian BC, Zhang WJ, Xu HM, Hao MX, Liu YB, Yang XG, Pan WS, Liu XH. Further investigation of nanostructured lipid carriers as an ocular delivery system: In vivo transcorneal mechanism and in vitro release study. Colloids Surf B Biointerfaces 2013; 102: 251-6.
12. Sivapriya V, Ponnarmadha S, Azeezand NA, Sudarshanadeepa V. Novel nanocarriers for ethnopharmacological formulation. Int J App Pharm 2018;10: 26-32.
13. Schuett BS, Millar TJ. An investigation of the likely role of (O-acyl) Ï‰-hydroxy fatty acids in meibomian lipid films using (O-oleyl) Ï‰-hydroxy palmitic acid as a model. Exp Eye Res2013; 115: 57-64.
14. Georgiev GA, Yokoi N, Ivanova S, Krastev R, Lalchev Z. Surface chemistry study of the interactions of pharmaceutical ingredients with human meibum films. Invest Ophthalmol Vis Sci 2012; 53: 4605-15.
15. Heurtault B, Saulnier P, Pech B, BenoÄ±Ì‚t JP, Proust JE. Interfacial stability of lipid nanocapsules. Colloids Surf B Biointerfaces 2003; 30: 225-35.
16. Herok GH, Mudgil P, Millar TJ. The effect of Meibomian lipids and tear proteins on evaporation rate under controlled in vitro conditions. Curr Eye Res 2009; 34: 589-97.
17. Bhamla MS, Chai C, Rabiah NI, Frostad JM, Fuller GG. Instability and Breakup of Model Tear Films. Invest Ophthalmol Vis Sci 2016; 57: 949-58.
18. Mudgil P, Torres M, Millar TJ. Adsorption of lysozyme to phospholipid and meibomian lipid monolayer films. Colloids Surf B Biointerfaces 2006; 48: 128-37.
19. Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm 2013; 39: 508-19.
20. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 2010; 17: 467-89.
21. Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 2008; 29: 1094-102.
22. Schuett BS, Millar TJ. An investigation of the likely role of (O-acyl) Ï‰-hydroxy fatty acids in meibomian lipid films using (O-oleyl) Ï‰-hydroxy palmitic acid as a model. Exp Eye Res 2013; 115: 57-64.